ORIGINAL ARTICLE

Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis

Nikolaus Jander,¹ Christa Gohlke-Bärwolf,¹ Edda Bahlmann,² Eva Gerdts,³ Kurt Boman,⁴ John B Chambers,⁵ Kenneth Egstrup,⁶ Christoph A Nienaber,⁷ Terje R Pedersen,⁸ Simon Ray,⁹ Anne B Rossebo,¹⁰ Ronnie Willenheimer,¹¹ Rolf-Peter Kienzle,¹ Kristian Wachtell,¹² Franz-Josef Neumann,¹ Jan Minners¹³

ABSTRACT

Background To account for differences in body size in patients with aortic stenosis, aortic valve area (AVA) is divided by body surface area (BSA) to calculate indexed AVA (AVAindex). Cut-off values for severe stenosis are <1.0 cm² for AVA and <0.6 cm²/m² for AVAindex.

Objective To investigate the influence of indexation on the prevalence of severe aortic stenosis and on the predictive accuracy regarding clinical outcome.

Methods Echocardiographic and anthropometric data from a retrospective cohort of 2843 patients with aortic stenosis (jet velocity >2.5 m/s) and from 1525 patients prospectively followed in the simvastatin and ezetimibe prospectively followed in the simvastatin and ezetimibe (jet velocity >2.5 m/s) and from 1525 patients prospectively followed in the simvastatin and ezetimibe (SEAS) trial were analysed.

Results The prevalence of severe stenosis increased with the AVAindex criterion compared to AVA from 71% to 80% in the retrospective cohort, and from 29% to 44% in SEAS (both p<0.001). Overall, the predictive accuracy for aortic valve events was virtually identical for AVA and AVAindex in the SEAS population (mean follow-up of 46 months; area under the receiver operating characteristic curve: 0.67 (95% CI 0.64 to 0.71) vs 0.68 (CI 0.65 to 0.71) (NS). However, 213 patients additionally categorised as severe by AVAindex experienced significantly less valve related events than those fulfilling only the AVA criterion (p<0.001).

Conclusions Indexing AVA by BSA (AVAindex) significantly increases the prevalence of patients with criteria for severe stenosis by including patients with a milder degree of the disease without improving the predictive accuracy for aortic valve related events.

INTRODUCTION

Indexing aortic valve area (AVA) by body surface area (BSA) (AVAindex) represents an intuitively convincing and widely adopted method to adjust for differences in body size.¹–³ Whereas current American College of Cardiology/American Heart Association guidelines on valvular heart disease recommend indexing AVA for all patients,² the recently published European Society of Cardiology (ESC) guidelines state that indexing ‘may be helpful, particularly in patients with an unusually small BSA’. In the European Association of Echocardiography/American Society of Echocardiography recommendations for clinical practice, the role of indexing is considered controversial particularly because of the uncertain role of excess body weight.⁴

Cut-off values for severe stenosis were set in all guidelines at <1.0 cm² for AVA and <0.6 cm²/m² for AVAindex. However, clinical or outcome studies supporting this recommendation are rare.⁵ In theory, calculation of AVAindex should not change the overall number of patients with severe stenosis in a given population but rather result in a decrease in the percentage of patients with the diagnosis of severe stenosis in smaller patients and an increase in larger patients. Based on the hypothesis that adjusting AVA by BSA, that is, AVAindex, improves the comparability of stenosis severity in patients with diverging body size we investigated the impact of AVAindex on the prevalence of severe aortic stenosis and the prediction of clinical events compared to (unindexed) AVA in two large populations of patients with aortic valve stenosis and normal left ventricular function.

PATIENTS AND METHODS

Data from two distinct study populations are presented. First, we identified 2843 consecutive patients investigated at the echocardiographic laboratory of the Heart Centre Bad Krozingen between January 1998 and December 2010 demonstrating normal left ventricular function and a jet velocity of ≥2.5 m/s. Patients with a moderate or severe mitral or aortic regurgitation, a mean pressure gradient <10 mm Hg or incomplete data were excluded. Normal left ventricular function was defined as normal global systolic left ventricular function with fractional shortening ≥30% without regional wall motion abnormalities.

The second cohort was recruited from the prospective SEAS study (NCT00092677), which enrolled 1873 patients with asymptomatic aortic stenosis, defined by echocardiography at local study centres as aortic valve thickening and transaortic Doppler jet velocity ≥2.5 and ≤4.0 m/s. Patients were randomised from January 2001 to February 2004 to at least 4-year placebo-controlled combined treatment with ezetimibe 10 mg/day and simvastatin 40 mg/day. Patients with coronary heart disease, heart failure, diabetes, history of stroke or peripheral vascular disease, clinically significant mitral valve disease, severe or predominant aortic regurgitation, rheumatic valvular disease, aortic valve prosthesis or renal insufficiency, and patients already on lipid-lowering therapy or having an indication for lipid lowering according to guidelines...
were excluded. The original SEAS study showed no difference in major cardiovascular events between treatment and placebo group but a significant reduction in ischaemic events in patients treated with ezetimibe/simvastatin.6 The present study population comprises 1525 (81.4%) of the 1873 patients recruited in the SEAS trial with an ejection fraction ≥55% in whom a detailed echocardiographic assessment by the core laboratory at baseline was available.

Echocardiography was performed following the guidelines for the clinical application of echocardiography4 7 8 and has been described in detail elsewhere.6 9 10 Severe aortic stenosis was defined according to current guidelines1 2 by an AVA<1.0 cm² and an AVAindex<0.6 cm²/m². The velocity ratio (VR) as a body size independent measure of aortic stenosis severity was calculated by the velocity time integral (VTI) of pulsed wave Doppler in the left ventricular outflow tract divided by the VTI of continuous Doppler through the aortic valve. Anthropometric data (height and weight) were recorded electronically at the time of echocardiography. BSA was calculated from the Mosteller formula11: BSA = \sqrt{\text{height} \times \text{weight}} / 3600. Body mass index (BMI) was calculated as BMI = weight/height². The primary end point of the outcome analysis of the present study was aortic valve related events (defined as aortic valve replacement, congestive heart failure due to aortic stenosis, or death from cardiovascular causes); the secondary end point was cardiovascular death. All end points had been adjudicated with a predefined end point committee blinded for study conduct and results in the original SEAS study.6 All statistics were performed using SPSS V.15.0 with continuous variables presented as mean±SD and categorical variables as percentages. Percentages were compared with the use of the Pearson χ² test. Receiver operating characteristic (ROC) curves were constructed to assess the sensitivity and specificity of parameters of AVA and an AVAindex and to compare their ability to predict aortic valve events or cardiovascular death. The comparison of areas under the ROC curves (AUC) was performed as recommended by DeLong et al.12 The Kaplan–Meier method was used to assess event-free survival with differences checked by means of the log-rank test. All testing was two-tailed, and p values of less than 0.05 were considered to indicate statistical significance.

RESULTS
Clinical, anthropometric and echocardiographic data of both the retrospective cohort from our centre including 2843 patients and the prospectively followed SEAS population (n=1525) are summarised in table 1. Whereas the retrospective cohort corresponds to the typically encountered patients with a wide range of aortic stenosis severity, including very severe stenosis, referred to a tertiary care centre, the SEAS population represents selected patients with low cardiovascular risk and predominantly mild to moderate stenosis.

Prevalence of severe aortic valve stenosis according to AVA and A VAindex
Indexation by BSA increased the prevalence of severe stenosis in the retrospective cohort from 71% (AVA<1.0 cm²) to 80% (AVAindex<0.6 cm²/m², p<0.001). In the prospective SEAS population there was a similar increase from 31% to 44% (p<0.001). The percentages related to gender are given in table 2.

To study the impact of indexation on patients with diverging body size, we stratified the populations according to BSA quartiles demonstrating a body size dependency of AVA in both populations to the effect that larger patients had a lower prevalence of severe stenosis (figure 1A, B, p for trend<0.001) whereas A VAindex was independent of BSA. Compared to A VA, A VAindex did not significantly decrease the percentage of patients with severe stenosis in small patients (BSA ≤1.75 m²: 81% vs 84%, NS, figure 1A), but augmented it in the three remaining quartiles in the retrospective cohort (BSA 1.76–1.88 m²: 81% vs 75%; BSA 1.89–2.03 m²: 77% vs 67%; BSA >2.03 m²: 80% vs 58%, all p<0.001). A similar pattern was found in the SEAS population (AVAindex vs A VA: BSA ≤1.76 m²: 43% vs 45%; BSA 1.77–1.89 m²: 43% vs 33%; BSA 1.90–2.03 m²: 44% vs 27%; BSA >2.03 m²: 45% vs 18%, all p<0.001 except A VAindex vs A VA: BSA ≤1.76 m², NS, figure 1B). Calculation of the body size independent VR confirmed

Table 1 Clinical, anthropometric and echocardiographic characteristics

<table>
<thead>
<tr>
<th></th>
<th>Retrospective cohort (n=2843)</th>
<th></th>
<th></th>
<th>SEAS cohort (n=1525)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Range</td>
<td>Mean</td>
<td>SD</td>
<td>Range</td>
</tr>
<tr>
<td>Age (years)</td>
<td>72.1</td>
<td>10.2</td>
<td>21–97</td>
<td>67.4</td>
<td>9.6</td>
<td>28–85</td>
</tr>
<tr>
<td>Female (%)</td>
<td>48</td>
<td></td>
<td></td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167.4</td>
<td>8.9</td>
<td>140–198</td>
<td>170.5</td>
<td>9.2</td>
<td>145–199</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>77.2</td>
<td>14.9</td>
<td>39–159</td>
<td>78.1</td>
<td>14.2</td>
<td>42–159</td>
</tr>
<tr>
<td>Body surface area (m²)</td>
<td>1.89</td>
<td>0.2</td>
<td>1.3–2.8</td>
<td>1.91</td>
<td>0.2</td>
<td>1.4–2.9</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.5</td>
<td>4.5</td>
<td>15.6–51.9</td>
<td>26.8</td>
<td>4.2</td>
<td>15.5–51.6</td>
</tr>
<tr>
<td>LV end-diastolic diameter (mm)</td>
<td>47.4</td>
<td>5.4</td>
<td>28–68</td>
<td>50.2</td>
<td>6.1</td>
<td>26–72</td>
</tr>
<tr>
<td>LV end-systolic diameter (mm)</td>
<td>28.5</td>
<td>4.9</td>
<td>11–66</td>
<td>31.6</td>
<td>5.3</td>
<td>16–52</td>
</tr>
<tr>
<td>Shortening fraction (%)</td>
<td>40.1</td>
<td>6.5</td>
<td>30–68</td>
<td>37.2</td>
<td>5.9</td>
<td>20–58</td>
</tr>
<tr>
<td>Ejection fraction (fechol%,)</td>
<td>64.8</td>
<td>7.6</td>
<td>51–91</td>
<td>66.4</td>
<td>7.5</td>
<td>40–88</td>
</tr>
<tr>
<td>LVOT diameter (mm)</td>
<td>20.5</td>
<td>2.1</td>
<td>14–31</td>
<td>21.9</td>
<td>2.6</td>
<td>14–32</td>
</tr>
<tr>
<td>LVOT flow velocity (m/s)</td>
<td>1.04</td>
<td>0.18</td>
<td>0.7–1.9</td>
<td>0.97</td>
<td>0.20</td>
<td>0.5–1.8</td>
</tr>
<tr>
<td>Jet velocity (m/s)</td>
<td>4.1</td>
<td>0.9</td>
<td>2.5–6.7</td>
<td>3.1</td>
<td>0.5</td>
<td>1.7–4.8</td>
</tr>
<tr>
<td>Mean pressure gradient (mm Hg)</td>
<td>40.4</td>
<td>17.6</td>
<td>10–117</td>
<td>22.9</td>
<td>8.8</td>
<td>6–64</td>
</tr>
<tr>
<td>Aortic valve area (cm²)</td>
<td>0.89</td>
<td>0.32</td>
<td>0.3–2.3</td>
<td>1.28</td>
<td>0.46</td>
<td>0.4–4.0</td>
</tr>
<tr>
<td>Aortic valve area index (cm²/m²)</td>
<td>0.47</td>
<td>0.16</td>
<td>0.2–1.1</td>
<td>0.67</td>
<td>0.23</td>
<td>0.2–1.9</td>
</tr>
<tr>
<td>Velocity ratio</td>
<td>0.27</td>
<td>0.08</td>
<td>0.1–0.5</td>
<td>0.34</td>
<td>0.10</td>
<td>0.1–0.8</td>
</tr>
</tbody>
</table>

LVOT, left ventricular outflow tract; SEAS, simvastatin and ezetimibe in aortic stenosis trial.6
comparable stenosis severity between quartiles (mean VR in the retrospective cohort: BSA ≤ 1.75 m²: 0.26±0.1; BSA 1.76–1.88 m²: 0.26±0.1; BSA 1.89–2.03 m²: 0.27±0.1; BSA >2.03 m²: 0.27±0.1; mean VR in the SEAS study: BSA ≤ 1.76 m²: 0.33±0.1; BSA 1.77–1.89 m²: 0.33±0.1; BSA 1.90–2.03 m²: 0.34±0.1; BSA>2.03 m²: 0.34±0.1).

Indexation has been recommended specifically in patients with a BSA<1.5 m² or a BMI<22.4 In our study patients with a BSA<1.5 m² were classified with severe stenosis in 95% before and 85% after indexation in the retrospective cohort (n=91, p<0.04) and in 47% vs 37% in SEAS (n=19, p=0.34). In patients with a BMI<22 indexation had no statistically significant effect on the prevalence of severe stenosis (retrospective cohort (n=228): 80% vs 77%, p=0.47, SEAS (n=154): 37% vs 40%, p=0.34). On the other hand and to exclude a potential influence of excess body weight,4 we repeated the analysis with the exclusion of obese patients (BMI ≥ 30) resulting in a mean BSA of 1.83 m² and 1.86 m² for the retrospective and the SEAS cohort, respectively. The pattern of increasing the prevalence of severe aortic stenosis in the two cohorts (overall retrospective cohort (n=2128): AVAindex 78% vs A VA 72%; overall SEAS (n=1227): 42% vs 31%, both p<0.001) as well as in the predefined BSA quartiles (data not shown) remained identical. When considering only normal weighed patients (BMI 18.5–24.9), severe stenosis was diagnosed according to AVAindex in 42.8% and according to A VA in 34.9% in the SEAS cohort (p=0.01, n=538). The corresponding values for the retrospective cohort (n=889) were 76.6% versus 74.4% which was no longer statistically significant (p=0.29).

Inconsistent grading

Indexation has also been recommended specifically in patients with ‘inconsistent grading’ (mean pressure gradient ≤40 mm Hg, AVA < 1.0 cm² or, inversely, mean pressure gradient >40 mm Hg and AVA ≥1.0 cm²) in order to reduce discrepancies in the assessment of stenosis severity by gradients and AVA.13 However, based on the cut-off value for severe stenosis of AVAindex 0.6 cm²/m² (and mean pressure gradient 40 mm Hg) the overall number of ‘inconsistently graded’ patients increased rather than decreased after indexation in both populations (retrospective cohort: from 26% to 32%; SEAS: from 30% to 42%; both p<0.001) and was unchanged even in the quartile with the smallest patients (retropective cohort: 33% vs 31%; SEAS study 42% vs 41%; both NS). Adjusting the cut-off to 0.5 cm²/m² as recently suggested by Michelena et al14 significantly decreased inconsistent grading in both populations (retrospective cohort: from 32% to 23%; SEAS: from 42% to 24%, both p<0.001).

Patient outcome according to AVA and AVAindex

In the prospectively followed cohort from SEAS (n=1525) there were 495 aortic valve events, consisting of 431 aortic valve

![Figure 1](https://example.com/figure1.png)

**Figure 1** Prevalence of severe aortic valve stenosis after stratification according to body surface area (BSA). The prevalence of patients with severe stenosis according to the aortic valve area (AVA) criterion (<1.0 cm²) is body size dependent in both the retrospective cohort (a) and the simvastatin and ezetimibe in aortic stenosis population (b), with a higher prevalence of severe stenosis in smaller patients. Calculation of AVAindex decreases body size dependency but increases the overall prevalence of severe stenosis compared to AVA (p<0.001) in all quartiles except in small patients (BSA≤1.75/1.76 m²). The percentage of severe aortic stenosis according to velocity ratio is given for comparison.
replacements, 21 heart failures due to progression of aortic stenosis and 43 cardiovascular deaths over a mean follow-up of 45.8 ±14.1 months. Predictive accuracy for aortic valve events was unchanged by indexation as quantified by the AUC (AUC for AVA: 0.67 (95% CI 0.64 to 0.70); AUC for AVA$_\text{index}$: 0.68 (CI 0.65 to 0.71); NS; figure 2A). When excluding aortic valve replacement from the combined endpoint, AVA was superior to AVA$_\text{index}$ in predicting the remaining 64 events of cardiovascular death and heart failure due to progression of aortic stenosis (AUC for AVA: 0.61 (CI 0.58 to 0.63) vs AVA$_\text{index}$: 0.58 (CI 0.55 to 0.60), p<0.01). There was no difference in predictive accuracy with respect to cardiovascular death alone between the two parameters of aortic valve stenosis severity (AUC for AVA: 0.61 (CI 0.58 to 0.63); AUC for AVA$_\text{index}$: 0.60 (CI 0.57 to 0.62), NS; figure 2B). To further analyse the effect of indexation on rates of clinical outcome we compared clinical events between the 470 patients with severe stenosis according to AVA with 213 patients additionally categorised as severe according and limited to the AVA$_\text{index}$ criterion. The latter were more often male, younger and had a higher BSA (all p<0.001). Over a mean follow-up of 46 months, outcome in the 213 patients was significantly better with respect to aortic valve related events (figure 3A, p<0.001) with a trend towards a lower cardiovascular mortality (figure 3B, p=0.09), indicating that indexing AVA by BSA and applying a cut-off value of 0.6 cm$^2$/m$^2$ increases the prevalence of severe aortic stenosis by including individuals with a milder degree of the disease.

**DISCUSSION**

Our data from two large, distinct cohorts totalling 4368 patients with a wide range of aortic valve stenosis severity indicate that indexation AVA by BSA (AVA$_\text{index}$) and applying the current partition value of 0.6 cm$^2$/m$^2$ significantly increases the number of patients with criteria for a severe stenosis by additionally including patients with a milder degree of the disease without improving the predictive accuracy for aortic valve related events and cardiovascular death.

The percentage of patients with criteria for severe stenosis may differ depending on the population investigated. We therefore studied two distinct cohorts, one drawn from our institutional database representing typical patients referred to a tertiary care centre with a wide range of aortic stenosis severity as indicated by a mean jet velocity of 4.1 m/s (range 2.5–6.7). The other cohort was from the SEAS study comprising a highly selected population of patients with predominantly mild to moderate stenosis with a low cardiovascular risk profile as specified in the exclusion criteria of the trial. Despite the marked differences between the two study populations there was an almost identical pattern with respect to the increases seen in severe stenosis after calculation of AVA$_\text{index}$.

In theory, calculation of AVA$_\text{index}$ should eliminate body size dependency of AVA and not change the overall number of patients with severe stenosis in a given population but rather result in a decrease in the percentage in smaller and an increase in larger patients. The effect of indexation on the prevalence of severe stenosis in the two patient populations investigated in the present report, however, is quite different from the expected effect. Although indexation of AVA by BSA (AVA$_\text{index}$) clearly reduced body size dependency of AVA, using the currently accepted cut-off value of 0.6 cm$^2$/m$^2$ for AVA$_\text{index}$ resulted in an increase of patients with criteria for severe stenosis over and above that seen with AVA (cut-off <1.0 cm$^2$) alone. Whereas small patients with a BSA≤1.75 m$^2$ had no significant change in the prevalence of severe aortic stenosis, AVA$_\text{index}$ resulted in an increase in the remaining patients (covering a BSA between 1.77 and 2.9 m$^2$). These findings may in large part be explained by a discrepancy between partition values. The current relation between AVA and AVA$_\text{index}$ is based on a BSA of 1.67 m$^2$ (since 1.0/1.67 yields 0.6), whereas in the current study populations totalling 4368 patients the mean BSA was 1.89 and 1.91 m$^2$, respectively.

**Special populations**

Even in the subgroups of ‘very small’ patients (BSA <1.5 or BMI<22) there was only a trend towards a reduction of the percentage of severe stenosis, a finding potentially due to small sample size. Similarly, the increase in patients with severe stenosis seen with indexation was markedly more pronounced in males than in females, possibly due to smaller body size in the latter. Interestingly, in a recent retrospective Japanese study in 103 comparatively small asymptomatic patients with mean BSA of 1.5±0.2 m$^2$, an AVA$_\text{index}$ of ≥0.6 cm$^2$/m$^2$ was frequently observed in patients with an AVA<1.0 cm$^2$ and an AVA$_\text{index}$ of <0.6 cm$^2$/m$^2$ was predictive of a poor outcome.

**Figure 2** Predictive accuracy of echocardiographic parameters for valve related events. Receiver operating characteristic (ROC) curves illustrating the predictive accuracy of aortic valve area (AVA) and body surface area adjusted AVA (AVA$_\text{index}$) for aortic valve related events (a) and for cardiovascular death (b) over 46 months of follow-up in 1525 patients with mild to moderate aortic valve stenosis from the simvastatin and ezetimibe in aortic stenosis study. Area under the ROC curve was similar between AVA and AVA$_\text{index}$ (NS).
On the other hand, the role of indexation of AVA by BSA in large patients has been challenged due to overcorrection by the potential influence of excess body weight. However, excluding patients with a BMI ≥ 30 did not change the pattern of increasing the prevalence of severe aortic stenosis in the predefined BSA quartiles. Therefore, the observed overcorrection in larger individuals is not a result of obesity.

Indexation has been recommended specifically in patients with the clinically challenging constellation of ‘inconsistent grading’ or ‘low gradient severe aortic stenosis’ in whom AVA indicates severe stenosis (<1.0 cm²), however, mean pressure gradient remains below 40 mm Hg despite normal ejection fraction and, therefore, does not fulfill the criterion of a severe stenosis. In theory, indexation should decrease not only the number of patients with severe stenosis but also the percentage of ‘inconsistent grading’ in small patients. In contrast, our results demonstrate that indexation of AVA in fact increases the overall number of patients with ‘inconsistent grading’ and does not reduce it even in the quartile with the smallest patients. Therefore, rather than improving the comparability of different parameters for the echocardiographic assessment of the severity of aortic stenosis, adjustment of AVA by BSA (AVA_{index}) with the current cut-off value of <0.6 cm²/m² augmented the already existing discrepancies in both populations investigated. However, adjusting the cut-off for severe stenosis to AVA_{index} <0.5 cm²/m² as recently suggested, substantially decreased inconsistent grading, supporting the notion that adjustment to the proposed values may be appropriate.

**Clinical implications**

Severe aortic stenosis is currently defined by a peak velocity >4.0 m/s, mean pressure gradient >40 mm Hg, AVA <1.0 cm² and AVA_{index} <0.6 cm²/m² in both European and North American guidelines. These different measures of stenosis severity should be interchangeable in the presence of normal flow conditions. However, recent studies have shown that AVA tends to overestimate stenosis severity in comparison to peak velocity and mean pressure gradient. Furthermore, AVA introduces a strong correlation to body size, hindering the comparability of the different parameters used. The present study clearly shows that indexation of AVA by BSA reduces body size dependency of AVA. However, using the current cut-off value AVA_{index} <0.6 cm²/m² results in a further increase in the number of patients with severe stenosis over and above that seen with AVA. Taken together our data demonstrate that the AVA_{index} criterion of <0.6 cm²/m² is too high, at least in predominantly Caucasian populations, and a cut-off <0.5 cm²/m² may be more appropriate. Importantly and as stated in the current guidelines, it should be kept in mind that ‘absolute cut-off points cannot be relied upon for clinical decision-making and should be considered in combination with flow rate, pressure gradients, ventricular function, size and wall thickness, degree of valve calcification and blood pressure, as well as functional status’.

**Limitations**

There are some limitations with this analysis. First, the calculations were performed on data from two mostly northern and western European patient populations and may not apply to populations with significantly different anthropometric characteristics. Second, alternative formulae for the assessment of BSA exist,
however calculation of BSA based on work by Dubois and Dubois\(^\text{17}\) did not change results significantly (data not shown). Third, the validity of linear adjustment of cardiac dimensions by BSA has been questioned\(^\text{18}\) and stratification of patients according to quartiles of BSA may therefore be an oversimplification with respect to the relationship between A\(A\)VA and body size. Forth, over-weight status may be a limitation of A\(A\)VA\(_{\text{index}}\)^\(^\text{14}\) since BSA corrects not only for individual body size but also for acquired fat tissue. The adequate method to correct for excess body weight has not been clarified yet, but obesity could have contributed to the increased prevalence of severe aortic stenosis in large individuals. However, restricting the analysis to normal weight patients retained the pattern of increasing prevalence of severe aortic stenosis by A\(A\)VA\(_{\text{index}}\) compared to A\(A\)VA.

**CONCLUSION**

Indexing A\(A\)VA by BSA and applying the current partition value of A\(A\)VA\(_{\text{index}}\) < 0.6 cm\(^2\)/m\(^2\) for severe stenosis increases the prevalence of severe aortic valve stenosis compared to unindexed A\(A\)VA by including individuals with a milder degree of disease without improving the predictive accuracy for clinical events.

**Author affiliations**

\(^1\)University Heart Centre Freiburg/Bad Krozingen, Bad Krozingen, Germany
\(^2\)Department of Cardiology, Asklepios Clinic St Georg, Hamburg, Germany
\(^3\)Institute of Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway
\(^4\)Department of Medicine, Skellefteå, Sweden/Institution of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
\(^5\)Cardiothoracic Centre, Guys–St Thomas Hospital Trust, London, UK
\(^6\)Department of Medical Research, OUH Svendborg Hospital, Svendborg, Sweden
\(^7\)Medizinische Klinik I, Universitätsklinikum Rostock, Rostock, Germany
\(^8\)Ullevål, Centre of Preventive Medicine, University of Oslo, Oslo, Norway
\(^9\)Department of Cardiology, University Hospitals of South Manchester, Manchester, UK
\(^10\)Division of Cardiology, Oslo University Hospital, Aker, Norway
\(^11\)Heart Health Group and Lund University, Malmö, Sweden
\(^12\)Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
\(^13\)Department of Cardiology, University Hospital Basel, Basel, Switzerland

**Contributors**

JM as corresponding author acts as guarantor. NJ, CGB and JM were involved in the study conception and design; acquisition, analysis and interpretation of data; drafted the article and had final approval of the manuscript. RK was involved in the study design, data acquisition and interpretation of data. EB, EG, KB, JBC, KE, CAN, TR, SBR, RW, KW and FN were involved in interpretation of data, revising the article, and final approval of the manuscript.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional unpublished data are available.

**REFERENCES**


